Evolving molecular therapy for chronic myeloid leukaemia—are we on target?

Author： Copland Mhairi   Jørgensen Heather G.   Holyoake Tessa L.  

Publisher： Maney Publishing

ISSN： 1024-5332

Source： Hematology, Vol.10, Iss.5, 2005-10, pp. : 349-359

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection

By Webb Michael  

International Journal of Hematology, Vol. 95, Iss. 5, 2012-05 ,pp. : 556-563

Springer Publishing Company

Access to resources Recommend Favorite

Co-existing chronic myeloid leukaemia and multiple myeloma: rapid response to lenalidomide during imatinib treatment

By Offiah C.  

International Journal of Hematology, Vol. 95, Iss. 4, 2012-04 ,pp. : 451-452

Springer Publishing Company

Access to resources Recommend Favorite

Μultiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia

By Galanopoulos A.  

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 281-282

Springer Publishing Company

Access to resources Recommend Favorite

Evolving Molecular-Based Targeted Therapy for Cancer: An Exciting Field

By Carneiro Benedito   Hsiao Katy   Khandekar Janardan  

Comprehensive Therapy, Vol. 31, Iss. 4, 2005-12 ,pp. : 299-305

Humana Press, Inc

Access to resources Recommend Favorite

A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia - a possible new therapeutic target

By Guenova Margarita L.   Michova Antoaneta   Balatzenko Gueorgui N.   Yosifov Deyan Y.   Stoyanov Nikolay   Taskov Hristo   Berger Martin R.   Konstantinov Spiro M.  

Hematology, Vol. 17, Iss. 3, 2012-05 ,pp. : 132-139

Maney Publishing

Access to resources Recommend Favorite